HOXD9 promotes the growth, invasion and metastasis of gastric cancer cells by transcriptional activation of RUFY3

HOXD9通过转录激活RUFY3促进胃癌细胞生长、侵袭和转移

阅读:13
作者:Huiqiong Zhu, Weiyu Dai, Jiaying Li, Li Xiang, Xiaosheng Wu, Weimei Tang, Yaying Chen, Qiong Yang, Mengwei Liu, Yizhi Xiao, Wenjing Zhang, Jianjiao Lin, Jing Wang, Guangnan Liu, Yong Sun, Ping Jiang, Guoxin Li, Aimin Li, Side Liu, Ye Chen, Jide Wang

Background

The transcription factor HOXD9 is one of the members of the HOX family, which plays an important role in neoplastic processes. However, the role of HOXD9 in the growth and metastasis of gastric cancer (GC) remains to be elucidated.

Conclusions

The evidence presented here suggests that the HOXD9-RUFY3 axis promotes the development and progression of human GC.

Methods

In vitro functional role of HOXD9 and RURY3 in GC cells was determined using the TMA-based immunohistochemistry, western blot, EdU incorporation, gelatin zymography, luciferase, chromatin Immunoprecipitation (ChIP) and cell invasion assays. In vivo tumor growth and metastasis were conducted in nude mice.

Results

HOXD9 is overexpressed in GC cells and tissues. The high expression of HOXD9 was correlated with poor survival in GC patients. Functionally, HOXD9 expression significantly promoted the proliferation, invasion and migration of GC cells. Mechanically, HOXD9 directly associated with the RUFY3 promoter to increase the transcriptional activity of RUFY3. Inhibition of RUFY3 attenuated the proliferation, migration and invasiveness of HOXD9-overexpressing GC cells in vitro and in vivo. Moreover, both HOXD9 and RUFY3 were highly expressed in cancer cells but not in normal gastric tissues, with their expressions being positively correlated. Conclusions: The evidence presented here suggests that the HOXD9-RUFY3 axis promotes the development and progression of human GC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。